Company name
NovaGo Therapeutics
Company profile
Novago Therapeutics, a Swiss biotech company, is advancing NG004, an antibody inhibiting Nogo-A, to promote nerve regeneration in acute spinal cord injury. Currently, NG004 is in Phase Ib trials across Europe (dosing completed, excellent profile so far). Clinical PoC trial preparation is well underway, with the anticipated first patient treated in summer 2026. NovaGo Therapeutics is raising funds for a Series B round (majority subscribed) to fund this clinical PoC.
Date, time and room information
Monday, May 4, 17:15 - 17:30, room Montreal
Category
Clinical stage development company
Title of the presentation
Development of antibody therapeutics to unlock nerve regeneration in spinal cord injury
Speaker information
| Name | Position | Institution |
|---|---|---|
| Stefan Moese |
